Clinicopathological characteristics | Cases n = 73 (%) | Mollicutes (%) | H. pylori (%) | F. nucleatum (%) | M. hyorhinis (%) | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
PCR Positive | P | PCR Positive | P | qPCR Positive | P | qPCR Positive | P | IHC Positive | P | ||
Gender | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Male | 54 (74.0) | 6 (11.1) | 0.781 | 4 (7.4) | 0.670 | 12 (22.2) | 0.142 | 4 (7.4) | 0.102 | 5 (8.5) a | 0.446 a |
Female | 19 (26.0) | 3 (15.8) | Â | 2 (10.5) | Â | 4 (21.1) | Â | 4 (21.1) | Â | 3 (14.3) a | Â |
Age | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 ≤ 59 | 18 (24.7) | 1 (5.6) | 0.553 | 2 (11.1) | 0.607 | 4 (22.2) | 0.030 | 1 (5.6) | 0.398 | 0 (0.0) a | 0.108 a |
 > 59 | 55 (75.3) | 8 (14.5) |  | 4 (7.3) |  | 15 (27.3) |  | 7 (12.7) |  | 8 (12.9) a |  |
Tumour size (cm) | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 ≤ 4 | 24 (32.9) | 4 (16.7) | 0.430 | 2 (8.3) | 0.980 | 6 (25.0) | 0.053 | 3 (12.5) | 0.768 | 4 (14.8) a | 0.306 a |
 > 4 | 49 (67.1) | 5 (10.2) |  | 4 (8.2) |  | 13 (26.5) |  | 5 (10.2) |  | 4 (7.5) a |  |
TNM staging | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
I/II | 20 (27.4) | 3 (15.0) | 0.670 | 1 (5.0) | 0.538 | 2 (10.0) | 4.040 | 3 (15.0) | 0.497 | 2 (8.7) a | 0.805 a |
III/IV | 53 (72.6) | 6 (11.3) | Â | 5 (9.4) | Â | 17 (32.1) | Â | 5 (9.4) | Â | 6 (10.5) a | Â |
Metastasis | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Positive | 41 (56.2) | 7 (17.1) | 0.163 | 6 (14.6) | 0.024 | 12 (29.3) | 0.326 | 6 (14.6) | 0.255 | 5 (10.9) a | 0.763 a |
Negative | 32 (43.8) | 2 (6.3) | Â | 0 (0.0) | Â | 7 (21.9) | Â | 2 (6.3) | Â | 3 (8.8) a | Â |
Regional lymph nodes | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
NX | 3 (4.1) | 0 (0.0) | 0.476 | 0 (0.0) | 0.196 | 0 (0.0) | 4.336 | 0 (0.0) | 0.366 | 2 (50.0) a | 0.064 a |
N0 | 28 (38.4) | 2 (7.1) | Â | 0 (0.0) | Â | 6 (21.4) | Â | 2 (7.1) | Â | 2 (6.9) a | Â |
N1 | 26 (35.6) | 3 (11.5) | Â | 4 (15.4) | Â | 8 (30.8) | Â | 2 (7.7) | Â | 2 (6.7) a | Â |
N2 | 12 (16.4) | 3 (25.0) | Â | 2 (16.7) | Â | 5 (41.7) | Â | 3 (25.0) | Â | 1 (7.7) a | Â |
N3 | 4 (5.5) | 1 (25.0) | Â | 0 (0.0) | Â | 0 (0.0) | Â | 1 (25.0) | Â | 1 (25.0) a | Â |
Lymphatic invasion | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Positive | 43 (58.9) | 7 (16.3) | 0.219 | 6 (13.9) | 0.033 | 13 (30.2) | 0.736 | 6 (13.9) | 0.327 | 4 (8.3) a | 0.543 a |
Negative | 30 (41.1) | 2 (6.7) | Â | 0 (0.0) | Â | 6 (20.0) | Â | 2 (6.7) | Â | 4 (12.5) a | Â |
Vascular invasion | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Positive | 11 (15.1) | 2 (18.2) | 0.522 | 2 (18.2) | 0.192 | 6 (54.5) | 3.421 | 1 (9.1) | 0.830 | 2 (14.3) a | 0.556 a |
Negative | 62 (84.9) | 7 (11.3) | Â | 4 (6.5) | Â | 13 (21.0) | Â | 7 (11.3) | Â | 6 (9.1) a | Â |
Tumour type (Lauren's Class.) 3 | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Intestinal | 39 (53.4)) | 2 (5.1) | 0.110 | 2 (5.1) | 0.028 | 6 (15.4) | 2.609 | 3 (7.7) | 0.564 | 1 (2.6) a | 0.077 a |
Diffuse | 33 (45.2 | 7 (21.2) | Â | 3 (9.1) | Â | 13 (39.4) | Â | 5 (15.2) | Â | 6 (18.2) a | Â |
Histopathological grade | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
GX | 1 (1.4) | 0 (0.0) | 0.109 | 1 (100.0) | 0.008 | 10 (25.6) | 1.331 | 0 (0.0) | 0.649 | 0 (0.0) a | 0.892 a |
G1 | 39 (53.4) | 2 (5.1) | Â | 2 (5.1) | Â | 0 (0.0) | Â | 3 (7.7) | Â | 4 (8.9) a | Â |
G2 | 31 (42.5) | 6 (19.4) | Â | 3 (9.7) | Â | 9 (29.0) | Â | 5 (16.1) | Â | 4 (12.5) a | Â |
G3 | 2 (2.7) | 1 (50.0) | Â | 0 (0.0) | Â | 0 (0.0) | Â | 0 (0.0) | Â | 2 (100.0) a | Â |
G4 | 0 (0.0) | 0 (0.0) | Â | 0 (0.0) | Â | 0 (0.0) | Â | 0 (0.0) | Â | 0 (0.0) a | Â |
Haemorrhage | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Positive | 30 (41.1) | 3 (10.0) | 0.395 | 3 (10.0) | 0.861 | 8 (26.7) | 0.084 | 3 (10.0) | 0.586 | 4 (13.3) a | 0.764 a |
Negative | 43 (58.9) | 6 (14.0) | Â | 3 (16.3) | Â | 11 (25.6) | Â | 5 (11.6) | Â | 4 (9.3) a | Â |
Inflammation | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Positive | 17 (23.3) | 3 (17.6) | 0.446 | 3 (17.6) | 0.106 | 5 (29.4) | 0.072 | 2 (11.8) | 0.903 | 2 (8.7) a | 0.805 a |
Negative | 56 (76.7) | 6 (10.7) | Â | 3 (5.4) | Â | 14 (25.0) | Â | 6 (10.7) | Â | 6 (10.5) a | Â |
Presence of eosinophils | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Positive | 13 (17.8) | 3 (23.1) | 0.194 | 2 (15.4) | 0.299 | 4 (30.8) | 0.087 | 2 (15.4) | 0.573 | 1 (6.7) a | 0.633 a |
Negative | 60 (82.2) | 6 (10.0) | Â | 4 (6.7) | Â | 15 (25.0) | Â | 6 (10.0) | Â | 7 (10.8) a | Â |
Presence of neutrophils | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Positive | 14 (19.2) | 2 (14.3) | 0.804 | 2 (14.3) | 0.358 | 2 (14.3) | 2.049 | 1 (7.1) | 0.611 | 1 (5.6) a | 0.475 a |
Negative | 59 (80.2) | 7 (11.9) | Â | 4 (6.8) | Â | 17 (28.9) | Â | 7 (11.9) | Â | 7 (11.3) a | Â |
Presence of macrophages | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Positive | 17 (23.3) | 0 (0.0) | 0.078 | 0 (0.0) | 0.159 | 3 (17.6) | 0.872 | 1 (5.9) | 0.444 | 0 (0.0) a | 0.096 a |
Negative | 56 (76.7) | 9 (16.1) | Â | 6 (10.7) | Â | 16 (28.6) | Â | 7 (12.5) | Â | 8 (13.1) a | Â |
Tissue necrosis | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Positive | 16 (21.9) | 4 (25.0) | 0.081 | 0 (0.0) | 0.176 | 5 (31.3) | 0.621 | 2 (12.5) | 0.823 | 3 (18.8) a | 0.192 a |
Negative | 57 (78.1) | 5 (8.8) | Â | 6 (10.5) | Â | 14 (24.6) | Â | 6 (10.5) | Â | 5 (7.8) a | Â |
Papillary arrangements | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Positive | 6 (8.2) | 3 (50.0) | 0.003 | 0 (0.0) | 0.444 | 0 (0.0) | 2.389 | 1 (16.7) | 0.640 | 2 (28.6) a | 0.086 a |
Negative | 67 (91.8) | 6 (9.0) | Â | 6 (9.0) | Â | 19 (28.4) | Â | 7 (10.4) | Â | 6 (8.2) a | Â |
Tumour location | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Cardia | 4 (5.5) | 1 (25.0) | 0.703 | 0 (0.0) | 0.365 | 0 (0.0) | 1.698 | 1 (25.0) | 0.759 | 0 (0.0) a | 0.881 a |
Body | 25 (34.2) | 4 (16.0) | Â | 4 (16.0) | Â | 6 (24.0) | Â | 2 (8.0) | Â | 3 (12.0) a | Â |
Antrum | 43 (58.9) | 4 (9.3) | Â | 2 (4.7) | Â | 13 (30.2) | Â | 5 (11.6) | Â | 5 (10.0) a | Â |
Body and Antrum | 1 (1.4) | 0 (0.0) | Â | 0 (0.0) | Â | 0 (0.0) | Â | 0 (0.0) | Â | 0 (0.0) | Â |